
LNTH · NASDAQ
Lantheus Holdings, Inc.
$101.14 -0.01 (-0.01%)
Company overview
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $6.6B
- Employees
- 808
- Headquarters
- Bedford, MA
- Website
- lantheus.com
- CEO
- Mary Anne Heino
- Listed
- June 25, 2015
- P/E
- 24.02
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.5B
- Gross profit
- $935M
- Operating income
- $290M
- EBITDA
- $370M
- Net income
- $279M
- EPS
- $4.21
- Total assets
- $2.3B
- Total debt
- $803,000
- Gross margin
- 60.48%
- Net margin
- 18.05%
- Earnings yield
- 4.16%
Showing FY 2025
News